0001209191-22-058136.txt : 20221121
0001209191-22-058136.hdr.sgml : 20221121
20221121162134
ACCESSION NUMBER: 0001209191-22-058136
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221121
FILED AS OF DATE: 20221121
DATE AS OF CHANGE: 20221121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Yea Christopher
CENTRAL INDEX KEY: 0001691102
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36830
FILM NUMBER: 221406020
MAIL ADDRESS:
STREET 1: ONE KENDALL SQUARE, BUILDING 200
STREET 2: SUITE 2203
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: KalVista Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001348911
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200915291
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0430
BUSINESS ADDRESS:
STREET 1: 55 CAMBRIDGE PARKWAY
STREET 2: SUITE 901E
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (857) 999-0075
MAIL ADDRESS:
STREET 1: 55 CAMBRIDGE PARKWAY
STREET 2: SUITE 901E
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Therapeutics, Inc.
DATE OF NAME CHANGE: 20140916
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery, Inc
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery Inc
DATE OF NAME CHANGE: 20060105
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-11-21
0
0001348911
KalVista Pharmaceuticals, Inc.
KALV
0001691102
Yea Christopher
C/O KALVISTA PHARMACEUTICALS, INC
55 CAMBRIDGE PARKWAY, SUITE 901E
CAMBRIDGE
MA
02142
0
1
0
0
Chief Development Officer
Common Stock
2022-11-17
4
M
0
1774
A
35371
D
Common Stock
2022-11-18
4
S
0
1139
5.44
D
34232
D
Restricted Stock Unit
2022-11-17
4
M
0
1774
0.00
D
Common Stock
1774
24833
D
Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
1/16th of the total restricted stock units subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, subject to continued service through each vesting date.
/s/ Benjamin L. Palleiko, Attorney-in-Fact
2022-11-21